Pacer Advisors Inc. Acquires 30,931 Shares of United Therapeutics Co. (NASDAQ:UTHR)

Pacer Advisors Inc. raised its holdings in shares of United Therapeutics Co. (NASDAQ:UTHR) by 5.5% in the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 597,634 shares of the biotechnology company’s stock after acquiring an additional 30,931 shares during the period. Pacer Advisors Inc.’s holdings in United Therapeutics were worth $210,869,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp raised its position in shares of United Therapeutics by 52.7% in the 2nd quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp now owns 8,565 shares of the biotechnology company’s stock valued at $2,728,000 after acquiring an additional 2,955 shares during the period. Toronto Dominion Bank raised its holdings in United Therapeutics by 0.8% in the second quarter. Toronto Dominion Bank now owns 4,525 shares of the biotechnology company’s stock worth $1,441,000 after purchasing an additional 37 shares during the period. Dark Forest Capital Management LP bought a new position in shares of United Therapeutics during the second quarter worth $400,000. MBB Public Markets I LLC acquired a new position in shares of United Therapeutics in the 2nd quarter valued at $1,079,000. Finally, The Manufacturers Life Insurance Company increased its position in shares of United Therapeutics by 37.3% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 98,783 shares of the biotechnology company’s stock valued at $31,467,000 after buying an additional 26,840 shares in the last quarter. Institutional investors and hedge funds own 94.08% of the company’s stock.

Insider Activity at United Therapeutics

In other news, Director Nilda Mesa sold 224 shares of United Therapeutics stock in a transaction that occurred on Friday, November 8th. The stock was sold at an average price of $412.28, for a total transaction of $92,350.72. Following the completion of the transaction, the director now directly owns 5,783 shares in the company, valued at approximately $2,384,215.24. The trade was a 3.73 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Judy D. Olian sold 1,750 shares of the stock in a transaction on Monday, November 11th. The shares were sold at an average price of $412.48, for a total value of $721,840.00. Following the completion of the sale, the director now owns 5,655 shares in the company, valued at approximately $2,332,574.40. This trade represents a 23.63 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 139,048 shares of company stock valued at $52,435,099. 11.90% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

UTHR has been the topic of several recent analyst reports. UBS Group lifted their target price on United Therapeutics from $415.00 to $475.00 and gave the stock a “buy” rating in a report on Wednesday, January 8th. The Goldman Sachs Group boosted their price objective on United Therapeutics from $243.00 to $302.00 and gave the company a “neutral” rating in a research report on Friday, November 1st. Argus raised their target price on shares of United Therapeutics from $360.00 to $400.00 and gave the stock a “buy” rating in a report on Thursday, October 31st. StockNews.com raised shares of United Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Thursday, January 16th. Finally, HC Wainwright increased their price objective on shares of United Therapeutics from $400.00 to $425.00 and gave the stock a “buy” rating in a research report on Thursday, October 31st. One research analyst has rated the stock with a sell rating, two have issued a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $378.36.

United Therapeutics Price Performance

United Therapeutics stock opened at $370.83 on Monday. The firm has a 50-day moving average of $365.19 and a 200-day moving average of $356.03. The company has a market cap of $16.56 billion, a price-to-earnings ratio of 16.29, a P/E/G ratio of 0.95 and a beta of 0.57. United Therapeutics Co. has a one year low of $208.62 and a one year high of $417.82.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings results on Wednesday, October 30th. The biotechnology company reported $6.39 earnings per share for the quarter, beating analysts’ consensus estimates of $6.16 by $0.23. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The firm had revenue of $748.90 million during the quarter, compared to the consensus estimate of $722.62 million. During the same period last year, the company earned $5.38 earnings per share. The business’s revenue was up 22.9% compared to the same quarter last year. As a group, sell-side analysts expect that United Therapeutics Co. will post 25.22 earnings per share for the current year.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.